What is Dostarlimab?
Business Standard - 05 Jul 2025What is Dostarlimab? ...
dostarlimab
What is Dostarlimab? ...
Dostarlimab: Review on success story and clinical trials
ScienceDirect.com - 08 Jan 2025Dostarlimab: Review on success story and clinical trials ...
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma
BMC Cancer - 01 Jul 2025STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma ...
Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited
European Commission - 08 May 2025Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited ...
A New Immune Treatment May Work Against Several Cancer Types
Time Magazine - 28 Apr 2025A New Immune Treatment May Work Against Several Cancer Types ...
Diagram depicting the action mechanism of dostarlimab against cancer...
researchgate.net - 20 May 2025Diagram depicting the action mechanism of dostarlimab against cancer... ...
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
Nature - 27 Feb 2025CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours ...
AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
Pharmacy Times - 28 Apr 2025AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment ...
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
OncLive - 28 Apr 2025Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
Early-Onset, Severe Immune-Mediated Hepatitis With Dostarlimab in a Patient With Endometrial Cancer: A Case Report
Journal of Hematology Oncology Pharmacy - 07 Apr 2025Early-Onset, Severe Immune-Mediated Hepatitis With Dostarlimab in a Patient With Endometrial Cancer: A Case Report ...
Dostarlimab May Eliminate Need for Surgery in Patients With dMMR Solid Tumors
Oncology Nurse Advisor - 17 Jun 2025Dostarlimab May Eliminate Need for Surgery in Patients With dMMR Solid Tumors ...
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
CancerNetwork - 16 Dec 2024Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer ...
FIRST/ENGOT-OV44 Trial Results at ASCO 2025: Dostarlimab Plus Niraparib Improves Progression-Free Survival in First-Line Advanced Ovarian Cancer
Oncodaily - 02 Jun 2025FIRST/ENGOT-OV44 Trial Results at ASCO 2025: Dostarlimab Plus Niraparib Improves Progression-Free Survival in First-Line Advanced Ovarian Cancer ...
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
ScienceDirect.com - 21 Jan 2025Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
CancerNetwork - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
Fig. 3. Interaction of PD1 and PDL1 in the absence and presence of...
researchgate.net - 03 Dec 2024Fig. 3. Interaction of PD1 and PDL1 in the absence and presence of... ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...